Abstract | OBJECTIVE: DESIGN: A prospective, open study. SETTING: A tertiary referral hospital. PATIENT: INTERVENTIONS: Patients received TMP (300 mg twice a week) for 2 weeks and, where no major reaction occurred, subsequently with TMP-SMX (160 and 800 mg per tablet, one tablet two times a day, twice a week). Patients who developed significant and persistent hypersensitivity ceased SMX and were subsequently challenged with TMP- dapsone (300 and 100 mg, respectively, twice a week). MAIN OUTCOME MEASURES: That rechallenge is more likely to be successful in those with advanced HIV disease. RESULTS: CONCLUSIONS: Rechallenge with TMP-SMX appears safe in HIV-infected patients with a history of non-life-threatening hypersensitivity and is most likely to be successful in patients with a low CD4+ lymphocyte count. The data suggest a low rate cross- hypersensitivity between SMX and dapsone, at least at the doses used.
|
Authors | A Carr, R Penny, D A Cooper |
Journal | AIDS (London, England)
(AIDS)
Vol. 7
Issue 1
Pg. 65-71
(Jan 1993)
ISSN: 0269-9370 [Print] England |
PMID | 8442919
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Trimethoprim, Sulfamethoxazole Drug Combination
|
Topics |
- AIDS-Related Opportunistic Infections
(prevention & control)
- Adult
- Cross Reactions
- Drug Eruptions
(complications, etiology, immunology)
- Drug Hypersensitivity
(complications, etiology, immunology)
- HIV Infections
(complications, drug therapy)
- Humans
- Male
- Pneumocystis Infections
(prevention & control)
- Safety
- Trimethoprim, Sulfamethoxazole Drug Combination
(administration & dosage, adverse effects, immunology)
|